Prosecution Insights
Last updated: November 20, 2026
Application No. 18/293,475

ANTISEPTIC COMPOSITION

Final Rejection §103§112
Filed
Jan 30, 2024
Priority
Aug 06, 2021 — JP 2021-129996 +1 more
Examiner
RODRIGUEZ, RAYNA B
Art Unit
1628
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Otsuka Pharmaceutical Co., Ltd.
OA Round
2 (Final)
33%
Grant Probability
At Risk
3-4
OA Rounds
8m
Est. Remaining
52%
With Interview

Examiner Intelligence

Grants only 33% of cases
33%
Career Allowance Rate
197 granted / 593 resolved
-26.8% vs TC avg
Strong +19% interview lift
Without
With
+19.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
62 currently pending
Career history
674
Total Applications
across all art units

Statute-Specific Performance

§101
2.0%
-38.0% vs TC avg
§103
48.3%
+8.3% vs TC avg
§102
12.9%
-27.1% vs TC avg
§112
21.5%
-18.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 593 resolved cases

Office Action

§103 §112
DETAILED ACTION This office action is in response to applicant’s filing dated July 1, 2026. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Notice of Change of Examiner Please note that the Examiner prosecuting this application has been changed to Examiner Rayna B. Rodriguez of Art Unit 1628. Please address all future correspondences to Examiner Rodriguez. Status of Claims Claims 9-28 are pending in the instant application. Acknowledgement is made of Applicant's remarks and amendments filed July 1, 2026. Acknowledgement is made of Applicant's amendment of claims 9, 10, 13, 14, 21-25, and 28. Claims 1-8 were previously canceled. Claims 9-28 are presently under examination. Priority The present application is a 371 of PCT/JP2022/029618 filed on August 2, 2022, which claims benefit of foreign priority to JAPAN 2021-129996 filed on August 6, 2021. Information Disclosure Statement The information disclosure statement (IDS) submitted on September 9, 2026 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner, except where marked with a strikethrough. Objections and/or Rejections and Response to Arguments Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated (Maintained Objections and/or Rejections) or newly applied (New Objections and/or Rejections, Necessitated by Amendment or New Objections and/or Rejections, NOT Necessitated by Amendment). They constitute the complete set presently being applied to the instant application. Withdrawn Objections and/or Rejections Claim Objections The objection to claims 6, 9, 10, and 13 has been rendered moot in view of the cancelation of claim 6 and the amendment of claims 9, 10, and 13. Thus, the objection has been withdrawn. Claim Rejections - 35 USC § 112(a) Scope of Enablement The rejection of claims 9-15 and 17-28 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for a method of disinfecting skin of a subject comprising applying a solution comprising a sugar alcohol and olanexidine gluconate, does not reasonably provide enablement for a method of applying a solution comprising a sugar alcohol and any microbicide has been rendered moot in view of the amendment of claim 9. Thus, the rejection has been withdrawn. Claim Rejections - 35 USC § 112(b) Indefinite The rejection of claims 14, 21-25, and 28 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention has been rendered moot in view of the amendment of claims 14, 21-25, and 28. Thus, the rejection has been withdrawn. New Objections and/or Rejections Necessitated by Claim Amendment Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 9-15 and 17-28 are rejected under 35 U.S.C. 103 as being unpatentable over Scholz (US 2009/0169647, cited in the IDS filed 08/14/2024) in view of Fisher Science Education (Iodine, Tincture ~2% Solution, Safety Data Sheet according to 29CFR1910/1200 and GHS Rev. 3, December 16, 2014). Regarding claim 9, Scholz teaches a method of disinfecting tissue of a subject comprising applying a composition to the tissue of the subject (claim 27) wherein the composition comprises an anti-microbial agent comprising iodine, a monosaccharide or a sugar alcohol, and a vehicle (claim 1) particularly for skin antisepsis (abstract). Scholz teaches a preferred active antimicrobial agent is elemental iodine (I2); as in most iodine-containing patient preps, other iodine-containing species may be present in addition to iodine, such as iodide (I-); and it is widely recognized that elemental iodine is the most active antimicrobial species [0038]. Moreover, Scholz teaches suitable vehicles include water and ethanol [0082]. Scholz does not explicitly teach the elemental iodine is an iodine tincture. However, Fisher Science Education teaches iodine tincture contains sodium iodide, water, iodine, and ethanol (page 2, Section 3). As such, since Scholz teaches a method of disinfecting skin comprising applying an anti-microbial composition comprising elemental iodine and a sugar alcohol, wherein the composition can comprise iodine-containing species such as iodide, water, and ethanol; and since Fisher Science Education teaches iodine tincture is a commercially available iodine composition comprising elemental iodine (iodine), an iodide (sodium iodide), water and ethanol, it would have been prima facie obvious for a person of ordinary skill in the art before the effective filing date of the claimed invention to utilize iodine tincture as the iodine in the method taught by Scholz with an expectation of success, since the prior art establishes that elemental iodine, iodide, sugar alcohol, water and ethanol are suitable in a composition for disinfecting skin and iodine tincture is a commercially available composition comprising elemental iodine (iodine), an iodide (sodium iodide), water and ethanol. Regarding the sugar alcohol content of instant claim 9, Scholz teaches sugar alcohols are preferably present in a concentration of at least 0.25 wt%, more preferably at least 0.5 wt-%, even more preferably at least 1 wt-%, even more preferably at least 2 wt-%, even more preferably at least 4 wt-%, and even more preferably at least 5 wt-%, based on the total weight of the composition; the concentration is typically adjusted to ensure improved antimicrobial performance [0048]. MPEP 2144.05 states: In the case where the claimed ranges “overlap or lie inside ranges disclosed by the prior art” a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990). Even a slight overlap in range establishes a prima facie case of obviousness. In re Peterson, 65 USPQ2d 1379, 1382 (Fed. Cir. 2003). Regarding claims 10, 11, and 17, Scholz teaches more preferred sugar alcohols are those derived from monosaccharides (i.e., alcohols of a monosaccharide) including xylitol, mannitol, or combinations thereof [0048]. Regarding claim 11, mannitol reads on a sugar alcohol has an action of enhancing an adhesion force of an incise drape on the skin surface of the subject after application of the antiseptic solution as evidenced by instant claim 17. Regarding claims 12, 13, 15, 18-20, and 26-28, Scholz teaches it is particularly desirable to add one or more thickening agents, particularly polymeric thickeners (which may be film-forming polymers), and/or film-forming polymers, to the antiseptic compositions to improve substantivity (e.g., resistance to wash off by blood and body fluid exposure), improve adhesion of PSA-coated products, increase viscosity to prevent dripping, etc, and/or reduce the tack of the compositions [0090]; in certain embodiments, preferred polymeric thickeners are vinyl polymers prepared from amine group-containing monomers [0102]; and useful herein are vinyl polymers such as polyvinyl alcohol and polyvinyl pyrrolidone [0114]. Regarding claim 13, polyvinyl alcohol and polyvinyl pyrrolidone read on the adhesive agent has an action of enhancing an adhesion force of an incise drape on the skin surface of the subject after application of the antiseptic solution as evidenced by instant claim 26. Regarding the concentration of the adhesive agent of instant claims 14 and 21-25, Scholz teaches in certain embodiments, one or more polymeric thickeners and/or film-forming polymers (preferably substantive film-forming polymeric thickeners), are present in the antiseptic composition in a total amount of at least 2 wt-% [0109]. MPEP 2144.05 states: In the case where the claimed ranges “overlap or lie inside ranges disclosed by the prior art” a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990). Even a slight overlap in range establishes a prima facie case of obviousness. In re Peterson, 65 USPQ2d 1379, 1382 (Fed. Cir. 2003). Taken together, all this would result in the practice of the method of claims 9-15 and 17-28 with a reasonable expectation of success. Maintained Objections and/or Rejections Claim Rejections - 35 USC § 103 Claims 9-28 are rejected under 35 U.S.C. 103 as being unpatentable over Miyata (US 2006/0189500 A1, cited in the IDS filed 08/14/2024). Regarding claims 9-11, 16, and 17, Miyata teaches a method of disinfecting or sterilizing an object, comprising contacting the object with an effective amount of a disinfectant (claim 16) wherein the disinfectant is an aqueous solution containing olanexidine and at least an equimolar amount of gluconic acid (claims 1 and 6). Myata teaches the disinfectant of the present invention can be suitably used for disinfecting skin/hands [0063]. Myata teaches in an aqueous solution containing olanexidine and at least an equimolar amount of gluconic acid, the olanexidine and the gluconic acid may form a salt, or the two may exist in free form, or the gluconic acid salt of olanexidine may coexist with free olanexidine and free gluconic acid [0030]. Thus, Miyata teaches a method of disinfecting skin comprising contacting skin with a disinfectant comprising olanexidine gluconate. Moreover, Miyata teaches if desired, additives used in preparations such as ordinary liquid preparations, ointments and the like can be suitably added to the disinfectant of present invention insofar as it does not adversely affect the dissolution of olanexidine in water; examples of such additives include moisturizers [0051]; and examples of moisturizers include mannitol [0053]. While the reference may not be anticipatory insofar as one must select moisturizer from various additives and further select mannitol from the disclosed moisturizers to disinfect skin as taught in Miyata, it remains that it would have been obvious to a person of ordinary skill in the art, to have selected a moisturizer, mannitol, in order to arrive at a composition useful for disinfecting skin. The skilled person would have been motivated to do so by the unambiguous disclosure of each particular species of additive and moisturizer agent individually and alternatively as equally useful in a method of disinfecting skin. This conclusion is supported by the fact that it has long been held in patent prosecution that a reference should be considered as expansively as is reasonably possible in determining the full scope of the contents within its four corners. Regarding the amount of the sugar alcohol of instant claim 9, Myata does not explicitly teach the claimed concentration. However, Myata does teach glycerol and glycerol triisooctanoate as alternatively useful moisturizers. Moreover, Myata teaches preparation example 11 [0090] comprising 240 mL of absolute ethanol, 15 g of glycerol, 15 g of glycerol triisooctanoate were added to 10 ml of Aqueous Solution 1 thus obtaining a hand disinfectant containing 0.2% olanexidine. An amount of 15 g of glycerol and 15 g of glycerol triisooctanoate is equivalent to an amount of about 3% glycerol and 3% glycerol triisooctanoate or 6% total moisturizer. It would have been prima facie obvious to one of ordinary skill in the art before the effective filing date to utilize the amounts of the disclosed moisturizers, glycerol and glycerol triisooctanoate taught by Myata as a starting point for optimizing the amount of the moisturizer, mannitol, for use in a composition comprising olanexidine gluconate and mannitol utilized to disinfect skin, since Myata teaches mannitol, glycerol and glycerol triisooctanoate as alternatively useful moisturizers is useful for disinfecting skin and because dosage and amounts are result-effective variables, i.e. a variable that achieves a recognized result. Therefore, the determination of the optimum or workable amounts would have been well within the practice of routine experimentation by the skilled artisan. Furthermore, absent any evidence demonstrating a patentable difference between the compositions and the criticality of the claimed dosage range, the determination of the optimum or workable dosing regimen given the guidance of the prior art would have been generally prima facie obvious to the skilled artisan. Please see MPEP 2144.05 [R-2](II)(A) and In re Aller, 220 F. 2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). ("[W]here the general conditions of claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation."). Regarding claim 11, mannitol reads on a sugar alcohol has an action of enhancing an adhesion force of an incise drape on the skin surface of the subject after application of the antiseptic solution as evidenced by instant claim 17. Taken together, all this would result in the method of claims 9-11, 16, and 17 with a reasonable expectation of success. Regarding claims 12, 13, 15, 18-20, and 26-28, Miyata teaches if desired, additives used in preparations such as ordinary liquid preparations, ointments and the like can be suitably added to the disinfectant of present invention insofar as it does not adversely affect the dissolution of olanexidine in water; examples of such additives include thickeners [0051]; and examples of thickeners include water-soluble polymers such as povidones and polyvinyl alcohols [0054]. Povidone is an alternative name of polyvinylpyrrolidone. Regarding claim 13, polyvinyl alcohol and povidone/polyvinyl pyrrolidone read on the adhesive agent has an action of enhancing an adhesion force of an incise drape on the skin surface of the subject after application of the antiseptic solution as evidenced by instant claim 26. It would have been prima facie obvious to one of ordinary skill in the art before the effective filing date to utilize a thickener, povidones and polyvinyl alcohols, in the disinfectant composition for disinfecting skin taught by Myata, since Myata establishes that these are suitable additives for such compositions. Taken together, all this would result in the practice of the method of claims 12, 13, 15, 18-20, and 26-28 with a reasonable expectation of success. Regarding the amount of polyvinyl alcohol of instant claims 14 and 21-25, Myata does not explicitly teach the claimed concentration. However, Myata does teach preparation example 12 [0091] comprising 6.3 g of a partially hydrolyzed polyvinyl alcohol, 1.8 g of !auric acid diethanolamide and 3.6 g of a polyethylene-polypropylene glycol added to 20 mL pf Aqueous solution 2 and purified water was added to give a final volume of 180 mL. An amount of 6.3 g of polyvinyl alcohol is equivalent to an amount of about 3.5% polyvinyl alcohol. glycerol and 3% glycerol triisooctanoate or 6% total moisturizer. It would have been prima facie obvious to one of ordinary skill in the art before the effective filing date to utilize the amount of polyvinyl alcohol taught by Myata as a starting point for optimizing the amount of polyvinyl alcohol for use in a composition comprising olanexidine gluconate, mannitol, and polyvinyl alcohol utilized to disinfect skin, since Myata teaches polyvinyl alcohol is useful in the disclosed compositions for disinfecting skin and because dosage and amounts are result-effective variables, i.e. a variable that achieves a recognized result. Therefore, the determination of the optimum or workable amounts would have been well within the practice of routine experimentation by the skilled artisan. Furthermore, absent any evidence demonstrating a patentable difference between the compositions and the criticality of the claimed dosage range, the determination of the optimum or workable dosing regimen given the guidance of the prior art would have been generally prima facie obvious to the skilled artisan. Please see MPEP 2144.05 [R-2](II)(A) and In re Aller, 220 F. 2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). ("[W]here the general conditions of claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation."). Taken together, all this would result in the practice of the method of claims 14 and 21-25 with a reasonable expectation of success. Response to Arguments Rejections over Scholz Applicant argues: Scholz is limited to iodine antimicrobial agent and specifically teaches away from iodine tincture. Examiner's response: The above argument has been carefully considered and has not been found persuasive. "A known or obvious composition does not become patentable simply because it has been described as somewhat inferior to some other product for the same use." In re Gurley, 27 F.3d 551, 554, 31 USPQ2d 1130, 1132 (Fed. Cir. 1994). The Examiner acknowledges that tincture of iodine is quite irritating to the skin. However, as set forth above, Scholz teaches a preferred active antimicrobial agent is elemental iodine (I2); as in most iodine-containing patient preps, other iodine-containing species may be present in addition to iodine, such as iodide (I-); and it is widely recognized that elemental iodine is the most active antimicrobial species. Moreover, as set forth above, Scholz teaches suitable vehicles include water and ethanol. As set forth above, Fisher Science Education teaches iodine tincture contains sodium iodide, water, iodine, and ethanol (page 2, Section 3). As such, since Scholz teaches a method of disinfecting skin comprising applying an anti-microbial composition comprising elemental iodine and a sugar alcohol, wherein the composition can comprise iodine-containing species such as iodide, water, and ethanol; and since Fisher Science Education teaches iodine tincture is a commercially available iodine composition comprising elemental iodine (iodine), an iodide (sodium iodide), water and ethanol, it would have been prima facie obvious for a person of ordinary skill in the art before the effective filing date of the claimed invention to utilize iodine tincture as the iodine in the method taught by Scholz with an expectation of success, since the prior art establishes that elemental iodine, iodide, sugar alcohol, water and ethanol are suitable in a composition for disinfecting skin and iodine tincture is a commercially available composition comprising elemental iodine (iodine), an iodide (sodium iodide), water and ethanol. Applicant argues: There is no teaching in Scholz as to adjusting the concentration of the sugar alcohol in the antiseptic composition to 1.0-10% (w/v) and the effect provided by doing so. By contrast, it is specifically shown by the results under sections "2-1," "2-2," etc. of present Examples (paragraphs [0043]-[0051]) that an addition sugar alcohol so that its concentration is 1.0-10% (w/v) to the antiseptic composition comprising a microbicide enhances the adhesion force of an incise drape on skin surface to which the antiseptic composition has been applied, as compared with the case of adding no sugar alcohol. Scholz fails to disclose or suggest this effect. Accordingly, the effect provided by the present invention of enhancing the adhesion force of an incise drape is totally opposite to that is usually expected, which can thus be said to be an advantageous effect that cannot be predicted from Scholz. Examiner's response: The above argument has been carefully considered and has not been found persuasive. As set forth above, Scholz teaches sugar alcohols are preferably present in a concentration of at least 0.25 wt%, more preferably at least 0.5 wt-%, even more preferably at least 1 wt-%, even more preferably at least 2 wt-%, even more preferably at least 4 wt-%, and even more preferably at least 5 wt-%, based on the total weight of the composition; the concentration is typically adjusted to ensure improved antimicrobial performance [0048]. MPEP 2144.05 states: In the case where the claimed ranges “overlap or lie inside ranges disclosed by the prior art” a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990). Even a slight overlap in range establishes a prima facie case of obviousness. In re Peterson, 65 USPQ2d 1379, 1382 (Fed. Cir. 2003). Thus, the teachings of Scholz render the instantly claimed concentration obvious. Rejections over Miyata Applicant argues: Claim 9 is currently amended to recite a sugar alcohol content of 1.0-10% (w/v), which Applicant submits is not disclosed or suggested by Miyata. Accordingly, Applicant submits that amended claim 9 is not disclosed or suggested by Miyata. Examiner's response: The above argument has been carefully considered and has not been found persuasive. As set forth above, Myata does teaches mannitol, glycerol and glycerol triisooctanoate as alternatively useful moisturizers. Moreover, Myata teaches preparation example 11 [0090] comprising 240 mL of absolute ethanol, 15 g of glycerol, 15 g of glycerol triisooctanoate were added to 10 ml of Aqueous Solution 1 thus obtaining a hand disinfectant containing 0.2% olanexidine. An amount of 15 g of glycerol and 15 g of glycerol triisooctanoate is equivalent to an amount of about 3% glycerol and 3% glycerol triisooctanoate or 6% total moisturizer. It would have been prima facie obvious to one of ordinary skill in the art before the effective filing date to utilize the amounts of the disclosed moisturizers, glycerol and glycerol triisooctanoate taught by Myata as a starting point for optimizing the amount of the moisturizer, mannitol, for use in a composition comprising olanexidine gluconate and mannitol utilized to disinfect skin, since Myata teaches mannitol, glycerol and glycerol triisooctanoate as alternatively useful moisturizers is useful for disinfecting skin and because dosage and amounts are result-effective variables, i.e. a variable that achieves a recognized result. Therefore, the determination of the optimum or workable amounts would have been well within the practice of routine experimentation by the skilled artisan. Furthermore, absent any evidence demonstrating a patentable difference between the compositions and the criticality of the claimed dosage range, the determination of the optimum or workable dosing regimen given the guidance of the prior art would have been generally prima facie obvious to the skilled artisan. Please see MPEP 2144.05 [R-2](II)(A) and In re Aller, 220 F. 2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). ("[W]here the general conditions of claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation."). Applicant argues: Claims 14 and 21-25 are not obvious over Miyata for the additional reason that Miyata does not disclose or suggest the content of the adhesive agent recited in those claims. The Office Action asserts that Miyata discloses (apparently in reference to Miyata Preparation Example 12) an olanexidine solution comprising 3.5% (w/v) polyvinyl alcohol. Even assuming (for the sake of argument) that the Office Actions allegations above were accurate, it should be clear that reducing the amount of polyvinyl alcohol would not adversely impact olanexidine solubility. Applicant submits that if any optimization of polyvinyl alcohol content in Miyata were studied, it would be to determine the maximum amount (if any) that that would not impact olanexidine dissolution. Clearly, a POSA would understand that olanexidine dissolution-the sole alleged "result effective variable" argued in the Office Action-would not be adversely impacted by decreasing the polyvinyl alcohol content. Moreover, as far as Applicant can identify, Miyata mentions polyvinyl alcohol exactly once: in Preparation Example 12 as discussed above. Miyata's failure to mention polyvinyl alcohol in its paragraph [0053] suggests that Miyata does not consider it to be a moisturizer. Therefore, Applicant submits that nothing in Miyata discloses or suggests any reason for "optimizing" its content in Preparation Example 12. Examiner's response: The above argument has been carefully considered and has not been found persuasive. As set forth above, Myata teaches the use of polyvinyl alcohol as a thickener. The skilled artisan would have a reasonable expectation of optimizing the amount of polyvinyl alcohol to achieve a desired thickness. If the desired thickness is a less thick composition, the skilled artisan would be motivated to reduce the amount of polyvinyl alcohol to reduce the thickness of the final composition. As set forth above, it would have been prima facie obvious to one of ordinary skill in the art before the effective filing date to utilize the amount of polyvinyl alcohol taught by Myata as a starting point for optimizing the amount of polyvinyl alcohol for use in a composition comprising olanexidine gluconate, mannitol, and polyvinyl alcohol utilized to disinfect skin, since Myata teaches polyvinyl alcohol is useful in the disclosed compositions for disinfecting skin and because dosage and amounts are result-effective variables, i.e. a variable that achieves a recognized result. Therefore, the determination of the optimum or workable amounts would have been well within the practice of routine experimentation by the skilled artisan. Furthermore, absent any evidence demonstrating a patentable difference between the compositions and the criticality of the claimed dosage range, the determination of the optimum or workable dosing regimen given the guidance of the prior art would have been generally prima facie obvious to the skilled artisan. Please see MPEP 2144.05 [R-2](II)(A) and In re Aller, 220 F. 2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). ("[W]here the general conditions of claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation."). Applicant argues: There is no teaching in Miyata as to adjusting the concentration of sugar alcohol in the antiseptic composition to 1.0-10% (w/v) and the effect provided by doing so. By contrast, it is specifically shown by the results under sections "2-1," "2-2," etc. of present Examples (paragraphs [0043]-[0051]) that an addition sugar alcohol so that its concentration is 1.0-10% (w/v) to the antiseptic composition comprising a microbicide enhances the adhesion force of an incise drape on skin surface to which the antiseptic composition has been applied, as compared with the case of adding no sugar alcohol. Miyata fails to disclose or suggest this effect. Indeed, Miyata discloses mannitol and xylitol as moisturizers (paragraph [0053]), and it is expected that an addition of sugar alcohol in Miyata would rather reduce the adhesion force. Accordingly, the effect provided by the present invention of enhancing the adhesion force of an incise drape is totally opposite to that is usually expected, which can thus be said to be an advantageous effect that cannot be predicted from Miyata. Examiner's response: The above argument has been carefully considered and has not been found persuasive. As set forth above, Myata does teaches mannitol, glycerol and glycerol triisooctanoate as alternatively useful moisturizers. Moreover, Myata teaches preparation example 11 [0090] comprising 240 mL of absolute ethanol, 15 g of glycerol, 15 g of glycerol triisooctanoate were added to 10 ml of Aqueous Solution 1 thus obtaining a hand disinfectant containing 0.2% olanexidine. An amount of 15 g of glycerol and 15 g of glycerol triisooctanoate is equivalent to an amount of about 3% glycerol and 3% glycerol triisooctanoate or 6% total moisturizer. It would have been prima facie obvious to one of ordinary skill in the art before the effective filing date to utilize the amounts of the disclosed moisturizers, glycerol and glycerol triisooctanoate taught by Myata as a starting point for optimizing the amount of the moisturizer, mannitol, for use in a composition comprising olanexidine gluconate and mannitol utilized to disinfect skin, since Myata teaches mannitol, glycerol and glycerol triisooctanoate as alternatively useful moisturizers is useful for disinfecting skin and because dosage and amounts are result-effective variables, i.e. a variable that achieves a recognized result. Therefore, the determination of the optimum or workable amounts would have been well within the practice of routine experimentation by the skilled artisan. Conclusion Claims 9-28 are rejected. No claim is allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to RAYNA B RODRIGUEZ whose telephone number is (571)272-7088. The examiner can normally be reached 8am-5:00pm ET, Monday - Thursday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L Clark can be reached at 571-272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Rayna Rodriguez/ Primary Examiner, Art Unit 1628
Read full office action

Prosecution Timeline

Jan 30, 2024
Application Filed
Apr 09, 2026
Non-Final Rejection mailed — §103, §112
Jul 01, 2026
Response Filed
Oct 23, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799064
STABLE EQUIVALENT OF RESOLVIN E2
4y 3m to grant Granted Nov 17, 2026
Patent 12778928
ANTI-INFLAMMATORY COMPOSITION COMPRISING BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVES
3y 9m to grant Granted Nov 03, 2026
Patent 12780867
STEROL BASED IONIZABLE LIPIDS AND LIPID NANOPARTICLES COMPRISING THE SAME
2y 1m to grant Granted Nov 03, 2026
Patent 12751951
CDK INHIBITORS
1y 4m to grant Granted Oct 06, 2026
Patent 12740983
CDK INHIBITORS
1y 4m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
33%
Grant Probability
52%
With Interview (+19.0%)
3y 5m (~8m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 593 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month